Joerg Reinhardt, Novartis COO
In its latest restructing, Novartis extended CEO Daniel Vasella's (photo) contract, and he tapped his vaccines and diagnostics chief, Joerg Reinhardt (pictured above), to be COO. Andrin Oswald (photo), chief of the recently acquired Speedel, will now take the helm at vaccines and diagnostics.
Related Articles:
Novartis to cut reps, reassign execs
Novartis: Data supports pre-pandemic vaccinations
Novartis buys Protez, invests in vaccines
Novartis injects $816.5M in vaccine plant
Novartis pays big for roster of new vaccines
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
